Document is current
Any future updates will be listed below
-
Authors
Gonzalez, Hector
McCarthy, Sean
Masterson, Claire
Byrnes, Declan
Sallent, Ignacio
Horan, Emma
Elliman, Stephen J.
Vella, Gabriele
Prina-Mello, Adriele
Silva, Johnatas D.
Krasnodembskaya, Anna D.
MacLoughlin, Ronan
Laffey, John G.
O’Toole, Daniel https://orcid.org/0000-0001-5422-8711
-
Funding
Funding for this research was provided by:
Health Research Board (ILP-POR-2017-024)
Science Foundation Ireland (13/RC/2073, 16-FRL-3845)
UK Research and Innovation (MR/R025096/1, MR/S009426/1)
Marie Skłodowska-Curie Actions (ALGORITM 895134)
- License Information
-
More Information
Article History
Received: 19 October 2022
Accepted: 24 May 2023
First Online: 6 June 2023
Declarations
:
: All handling of donor samples and data adhered to the Declaration of Helsinki protocols. BM-MSC production: Mesenchymal stem cells to patients with no option critical limb ischaemia. Galway University Hospital Clinical Research Ethics Committee. Approval 15/12, 14th December 2016. UC-MSC production: Novel stromal cell therapy for diabetic kindey disease. Galway University Hospital Clinical Research Ethics Committee. Approval 59/12, 15th May 2019.LPS-induced lung injury mouse model: Stem cell therapy approaches to ARDS therapeutics. Animal Welfare Ethical Review Body of Queen's University Belfast. Approval 2887, 20th April 2020. E. coli induced pneumonia rat model: Assessment of a Nebulised Delivery System for Enhanced Therapeutics for Acute and Chronic Respiratory Disease. Animal Care in Research Ethical Committee of University of Galway. Approval 17-Apr-02, 17th April 2017.
: Not applicable.
: Ms. Emma Horan is a Research Scientist and Dr. Stephen Elliman is Chief Scientific Officer at Orbsen Therapeutics Ltd., Galway Ireland. Dr. Ronan MacLoughlin is Chief Scientific Officer at Aerogen Ltd., Galway, Ireland. No other authors have any conflict of interest to declare.
